Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pelthos Therapeutics (PTHS) Cash from Operations (2024 - 2025)

Pelthos Therapeutics has reported Cash from Operations over the past 2 years, most recently at 6252000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 6252000.0 for Q4 2025, down 833.13% from a year ago — trailing twelve months through Dec 2025 was 22590000.0 (down 290.02% YoY), and the annual figure for FY2025 was 22590000.0, down 290.02%.
  • Cash from Operations for Q4 2025 was 6252000.0 at Pelthos Therapeutics, up from 15258729.0 in the prior quarter.
  • Over the last five years, Cash from Operations for PTHS hit a ceiling of 177692.0 in Q3 2024 and a floor of 15258729.0 in Q3 2025.